Bayesian Capital Management LP bought a new position in Chemours Company (The) (NYSE:CC) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 7,800 shares of the specialty chemicals company’s stock, valued at approximately $296,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in CC. Zacks Investment Management raised its stake in Chemours Company (The) by 1.6% during the 2nd quarter. Zacks Investment Management now owns 62,894 shares of the specialty chemicals company’s stock valued at $2,385,000 after purchasing an additional 973 shares during the period. OxFORD Asset Management LLP purchased a new stake in shares of Chemours Company (The) in the second quarter valued at $9,961,000. Virtu KCG Holdings LLC lifted its holdings in shares of Chemours Company (The) by 1,274.5% in the second quarter. Virtu KCG Holdings LLC now owns 82,500 shares of the specialty chemicals company’s stock valued at $3,128,000 after purchasing an additional 76,498 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Chemours Company (The) by 10.3% in the second quarter. Renaissance Technologies LLC now owns 3,342,200 shares of the specialty chemicals company’s stock worth $126,736,000 after buying an additional 310,800 shares during the period. Finally, Advisor Group Inc. boosted its position in shares of Chemours Company (The) by 76.2% in the second quarter. Advisor Group Inc. now owns 9,048 shares of the specialty chemicals company’s stock worth $291,000 after buying an additional 3,912 shares during the period. Institutional investors own 72.90% of the company’s stock.

Chemours Company (CC) opened at 52.75 on Tuesday. The stock has a market capitalization of $9.75 billion, a PE ratio of 34.52 and a beta of 3.60. Chemours Company has a 12-month low of $14.41 and a 12-month high of $52.75. The stock’s 50 day moving average is $50.84 and its 200 day moving average is $50.84.

Chemours Company (The) (NYSE:CC) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.02. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The business’s revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.27 earnings per share. Analysts forecast that Chemours Company will post $3.51 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 17th were given a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 0.23%. The ex-dividend date of this dividend was Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is 8.11%.

COPYRIGHT VIOLATION WARNING: “Bayesian Capital Management LP Acquires New Position in Chemours Company (The) (CC)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/03/bayesian-capital-management-lp-acquires-new-position-in-chemours-company-the-cc.html.

In related news, SVP David C. Shelton sold 13,337 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $48.48, for a total value of $646,577.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Amy Trojanowski sold 2,500 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.03, for a total transaction of $115,075.00. The disclosure for this sale can be found here. Insiders have sold 38,837 shares of company stock valued at $1,865,603 in the last three months. 1.14% of the stock is owned by insiders.

CC has been the topic of a number of research analyst reports. BidaskClub downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a report on Saturday, June 17th. Citigroup Inc. increased their price objective on Chemours Company (The) from $45.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 4th. Jefferies Group LLC reissued a “buy” rating and issued a $50.00 price objective (up from $48.00) on shares of Chemours Company (The) in a research note on Thursday, July 13th. UBS AG upgraded Chemours Company (The) from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $36.00 to $50.00 in a research report on Monday, August 7th. Finally, Zacks Investment Research lowered Chemours Company (The) from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 12th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $51.50.

Chemours Company (The) Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.